A-Methapred: Uses, Dosage, Side Effects

A-Methapred: Uses, Dosage, Side Effects

A-Methapred (methylprednisolone sodium succinate for infusion, USP) sterile powder contains methylprednisolone sodium succinate as the dynamic fixing. Methylprednisolone sodium succinate, USP, happens as a white, or almost white, scentless hygroscopic, indistinct strong. It is solvent in water and in liquor; it is insoluble in chloroform and is all around somewhat dissolvable in CH3)2CO. 

The compound name for methylprednisolone sodium succinate is pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxo-propoxy)- 11,17-dihydroxy-6-methyl-monosodium salt, (6a, 11ß), and the atomic weight is 496.53.


Generic Name: methylprednisolone sodium succinate


A-Methapred Indications:

At the point when oral treatment isn't doable, and the quality, dose structure and course of organization of the medication sensibly loan the readiness to the treatment of the condition, A-Methapred (methylprednisolone sodium succinate) clean powder is demonstrated for intravenous or intramuscular use in the accompanying conditions: 

Endocrine Disorders 

Essential or optional adrenocortical inadequacy (hydrocortisone or cortisone is the medication of decision; engineered analogs might be utilized related to mineralocorticoids where material; in earliest stages, mineralocorticoid supplementation is of specific significance) 

Intense adrenocortical inadequacy (hydrocortisone or cortisone is the medication of decision; mineralocorticoid supplementation might be essential, especially when engineered analogs are utilized) 

Preoperatively and in case of genuine injury or disease, in patients with known adrenal inadequacy or when adrenocortical save is far fetched 

Stun lethargic to traditional treatment if adrenocortical deficiency exists or is suspected 

Inherent adrenal hyperplasia 

Hypercalcemia related with malignant growth 

Nonsuppurative thyroiditis 

Rheumatic Disorders 

As adjunctive treatment for momentary organization (to hold the patient over an intense scene or intensification) in: 

Post-horrendous osteoarthritis 

Synovitis of osteoarthritis 

Rheumatoid joint pain, including adolescent rheumatoid joint pain (chose cases may require low-portion upkeep treatment) 

Intense and subacute bursitis 


Intense nonspecific tenosynovitis 

Intense gouty joint pain 

Psoriatic joint pain 

Ankylosing spondylitis 

Collagen Diseases 

Amid a worsening or as upkeep treatment in chose instances of: 

Fundamental lupus erythematosus 

Fundamental dermatomyositis (polymyositis) 

Intense rheumatic carditis 

Dermatologic Diseases 


Extreme erythema multi-forme (Stevens-Johnson disorder) 

Exfoliative dermatitis 

Bullous dermatitis herpetiformis 

Extreme seborrheic dermatitis 

Extreme psoriasis 

Mycosis fungoides 

Hypersensitive States 

Control of extreme or debilitating hypersensitive conditions recalcitrant to satisfactory preliminaries of customary treatment in: 

Bronchial asthma 

Contact dermatitis 

Atopic dermatitis 

Serum affliction 

Occasional or perpetual hypersensitive rhinitis 

Medication excessive touchiness responses 

Urticarial transfusion responses 

Intense noninfectious laryngeal edema (epinephrine is the medication of first decision) 

Ophthalmic Diseases 

Serious intense and endless unfavorably susceptible and provocative procedures including the eye, for example, 

Herpes zoster ophthalmicus 

Iritis, iridocyclitis 


Diffuse back uveitis and choroiditis 

Optic neuritis 

Thoughtful ophthalmia 

Foremost fragment irritation 

Unfavorably susceptible conjunctivitis 

Unfavorably susceptible corneal minor ulcers 


Gastrointestinal Diseases 

To hold the patient over a basic time of the illness in: 

Ulcerative colitis (foundational treatment) 

Territorial enteritis (foundational treatment) 

Respiratory Diseases 

Symptomatic sarcoidosis 


Blasting or scattered aspiratory tuberculosis when utilized simultaneously with fitting antituberculous chemotherapy 

Loeffler's disorder not sensible by different methods 

Goal pneumonitis 

Hematologic Disorders 

Obtained (immune system) hemolytic sickliness 

Idiopathic thrombocytopenic purpura in grown-ups (IV just; IM organization is contraindicated) 

Auxiliary thrombocytopenia in grown-ups 

Erythroblastopenia (RBC iron deficiency) 

Inherent (erythroid) hypoplastic sickliness 

Neoplastic Diseases 

For palliative administration of: 

Leukemias and lymphomas in grown-ups 

Intense leukemia of youth 

Edematous States 

To incite diuresis or abatement of proteinuria in the nephrotic disorder, without uremia, of the idiopathic sort or that because of lupus erythematosus 

Sensory system 

Intense intensifications of numerous sclerosis 


Tuberculous meningitis with subarachnoid square or looming square when utilized simultaneously with fitting antituberculous chemotherapy 

Trichinosis with neurologic or myocardial association


A-Methapred Dosage:

At the point when high portion treatment is wanted, the prescribed portion of A-Methapred (methylprednisolone sodium succinate) sterile powder is 30 mg/kg regulated intravenously over something like 30 minutes. This portion might be rehashed each 4 to 6 hours for 48 hours. 

By and large, high portion corticosteroid treatment ought to be proceeded with just until the patient's condition has balanced out; more often than not past 48 to 72 hours. 

Albeit unfavorable impacts related with high portion momentary corticoid treatment are extraordinary, peptic ulceration may happen. Prophylactic stomach settling agent treatment might be shown. 

In different signs beginning measurement will fluctuate from 10 to 40 mg of methylprednisolone relying upon the clinical issue being dealt with. The bigger portions might be required for momentary administration of extreme, intense conditions. The underlying portion more often than not ought to be given intravenously over a time of a few minutes. Ensuing dosages might be given intravenously or intramuscularly at interims directed by the patient's reaction and clinical condition. Corticoid treatment is an assistant to, and not substitution for traditional treatment. 

Measurement might be decreased for newborn children and youngsters however ought to be represented more by the seriousness of the condition and reaction of the patient than by age or size. It ought not be under 0.5 mg/kg at regular intervals. 

Dose must be diminished or suspended progressively when the medication has been controlled for in excess of a couple of days. In the event that a time of unconstrained abatement happens in an unending condition, treatment ought to be suspended. Routine research center examinations, for example, urinalysis, two-hour postprandial glucose, assurance of circulatory strain and body weight, and a chest X-beam ought to be made at customary interims amid delayed treatment. Upper GI X-beams are attractive in patients with a ulcer history or huge dyspepsia. 

A-Methapred (methylprednisolone sodium succinate) might be controlled by intravenous or intramuscular infusion or by intravenous imbuement, the favored technique for introductory crisis use being intravenous infusion. To regulate by intravenous (or intramuscular) infusion, plan arrangement as coordinated. The ideal portion might be controlled intravenously over a time of a few minutes. 

To get ready answers for intravenous imbuement, first set up the answer for infusion as coordinated. This arrangement may then be added to showed measures of 5% dextrose in water, isotonic saline arrangement or 5% dextrose in isotonic saline arrangement. 

Numerous Sclerosis 

In treatment of intense intensifications of numerous sclerosis, day by day dosages of 200 mg of prednisolone for seven days pursued by 80 mg each other day for multi month have been appeared to be compelling (4 mg of methylprednisolone is equal to 5 mg of prednisolone)

A-Methapred Side Effects:

Liquid and Electrolyte Disturbances 

Sodium maintenance, Fluid maintenance, Congestive heart disappointment in powerless patients, Potassium misfortune, Hypokalemic alkalosis, Hypertension 


Muscle shortcoming, Steroid myopathy, Loss of bulk, Severe arthralgia, Vertebral pressure breaks, Aseptic corruption of femoral and humeral heads, Pathologic crack of long bones, Osteoporosis 


Peptic ulcer with conceivable aperture and drain, Pancreatitis, Abdominal expansion, and Ulcerative esophagitis 


Weakened injury recuperating, Thin delicate skin, Petechiae and ecchymoses, Facial erythema, Increased perspiring, May smother responses to skin tests 


Expanded intracranial weight with papilledema (pseudo-tumor cerebri) as a rule after treatment, Convulsions, Vertigo, Headache 


Improvement of Cushingoid state, Suppression of development in youngsters, Secondary adrenocortical and pituitary lethargy, especially in the midst of worry, as in injury, medical procedure or ailment, Menstrual inconsistencies, Decreased sugar resilience, Manifestations of dormant diabetes mellitus, Increased necessities for insulin or oral hypoglycemic specialists in diabetics 


Back subcapsular waterfalls, Increased intraocular weight, Glaucoma, Exophthalmos 


Negative nitrogen funds receivable to protein catabolism 

The accompanying extra unfriendly responses are identified with parenteral corticosteroid treatment: Hyperpigmentation or hypopigmentation, Subcutaneous and cutaneous decay, Sterile sore, Anaphylactic response with or without circulatory breakdown, heart failure, bronchospasm, Urticaria, Nausea and spewing, Cardiac arrhythmias; hypotension or hypertension.

Tags: A-Methapred

* External A-Methapred Links:

A-METHAPRED (methylprednisolone sodium succinate)

FDA information on A-METHAPRED